NTRB
Nutriband Inc. NASDAQ Listed Oct 1, 2021$3.30
+3.45%
vs $3.19
Mkt Cap $40.1M
52w Low $2.80
8.6% of range
52w High $8.63
50d MA $3.12
200d MA $4.09
P/E (TTM)
—
EV/EBITDA
—
P/B
5.8x
Debt/Equity
0.0x
ROE
-123.2%
P/FCF
-7.5x
RSI (14)
67.40
ATR (14)
$0.11
Beta
1.93
50d MA
$3.12
200d MA
$4.09
Avg Volume
9.3K
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
121 South Orange Avenue · Orlando, FL 32801 · US
Data updated apr 26, 2026 4:01pm
· Source: financialmodelingprep.com